Haemonetics Corporation (HAE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Haemonetics Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 85.50 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 4.5% failed
- More than 10% revenue growth is expected for the coming year 5.3% failed
- Share count grows by less than 3% a year -2.7% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 17.6% failed
- Gross margin at 40% or higher and without meaningful erosion 55.7% passed
- Goodwill from acquisitions does not grow faster than revenue 27.4% failed
- Net debt below twice EBITDA 3.1 x EBITDA failed
- Operating cash flow covers the profits of the last three years 274 m passed
- Return on capital at 15% or higher, or up versus two years ago 11.4% passed
- Insiders hold at least 10% or are net buyers 1.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 2.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 03/31/2027 | 5.22 | 5.17 – 5.26 | 1,402 | 5.2% | 11 |
| 03/31/2028 | 5.63 | 4.79 – 5.85 | 1,474 | 7.8% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.07 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.74 | 21.90 | 349 | 3.70 | 10.80 | 44 | 35 |
| 2025: Q1 | 1.17 | 195.80 | 331 | -3.70 | 17.50 | 117 | 101 |
| 2025: Q2 | 0.70 | -5.40 | 321 | -4.40 | 10.60 | 17 | 14 |
| 2025: Q3 | 0.81 | 22.90 | 327 | -5.30 | 11.80 | 111 | 106 |
| 2025: Q4 | 0.95 | 28.60 | 339 | -2.70 | 13.20 | 94 | 87 |
| 2026: Q1 | -0.44 | -137.20 | 346 | 4.80 | -5.80 | 71 | 53 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 886 | -19 | -26 | -0.51 | 160 | 740 | 1,239 |
| 2018 | 904 | 56 | 46 | 0.85 | 220 | 752 | 1,237 |
| 2019 | 968 | 84 | 55 | 1.04 | 159 | 668 | 1,275 |
| 2020 | 988 | 103 | 77 | 1.48 | 158 | 587 | 1,267 |
| 2021 | 870 | 90 | 79 | 1.55 | 109 | 732 | 1,820 |
| 2022 | 993 | 81 | 43 | 0.84 | 172 | 749 | 1,860 |
| 2023 | 1,169 | 156 | 115 | 2.24 | 273 | 818 | 1,935 |
| 2024 | 1,309 | 165 | 118 | 2.29 | 182 | 960 | 2,196 |
| 2025 | 1,361 | 222 | 168 | 3.31 | 182 | 821 | 2,451 |
| 2026 | 1,334 | 241 | 97 | 2.05 | 293 | 796 | 2,396 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Haemonetics Corporation, ein Medizintechnikunternehmen, bietet eine Reihe von Krankenhaustechnologielösungen an. Das Unternehmen ist in drei Segmenten tätig: Plasma, Blood Center und Hospital.
| Employees | 3,009 |
|---|---|
| Headquarters | Boston, MA |
| Address | 125 Summer Street, 02110 Boston, United States |
| Phone | 781 848 7100 |
| Website | haemonetics.com |
| IPO Date | 9. May 1991 |
| ISIN | US4050241003 |
| Stock Split | 2:1 on 12/03/2012 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher A. Simon | CEO, President & Director | 1964 |
| James C. D'Arecca CPA | CFO, Executive VP & Financial Officer | 1971 |
| Frank W. Chan Ph.D. | Executive VP & COO | 1970 |
| Michelle L. Basil Esq., J.D. | Executive VP, General Counsel & Secretary | 1973 |
| Roy Galvin | Executive VP & Chief Commercial Officer | 1970 |
| Farris Maryanne E. Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | 1976 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 24. Jul 2026 | Madaus Martin D | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Zane Ellen M | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Pomeroy Claire | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Kroll Mark W | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Johnson Lloyd Emerson | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Coyle Michael J | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Bryant Diane M | Director | Other | 2,538 | – | – |
| 24. Jul 2026 | Abernathy Robert E | Director | Other | 2,538 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.